Isoform Positions

Isoform Protein Position Transcript Position Chromosomal Position (HG38) Chromosomal Position (HG19)
IC2588677881;77882;77883 chr2:178568476;178568475;178568474chr2:179433203;179433202;179433201
N2AB2424572958;72959;72960 chr2:178568476;178568475;178568474chr2:179433203;179433202;179433201
N2A2331870177;70178;70179 chr2:178568476;178568475;178568474chr2:179433203;179433202;179433201
N2B1682150686;50687;50688 chr2:178568476;178568475;178568474chr2:179433203;179433202;179433201
Novex-11694651061;51062;51063 chr2:178568476;178568475;178568474chr2:179433203;179433202;179433201
Novex-21701351262;51263;51264 chr2:178568476;178568475;178568474chr2:179433203;179433202;179433201
Novex-3NoneNone chr2:Nonechr2:None

Information

  • RefSeq wild type amino acid: V
  • RefSeq wild type transcript codon: GTA
  • RefSeq wild type template codon: CAT
  • Domain: Ig-136
  • Domain position: 89
  • Structural Position: 177
  • Q(SASA): 0.8528
  • Predicted PPI site: N

Reported SAVs

SNV RS
DUET
PolyPhen-2
Condel
Rhapsody
REVEL
MVP
Source
MAF
Disease
Zygosity
Site annotation
mCSM PPI
Predicted PPI site
Comments
AFR
AMR
AMS
ASJ
EAS
EUR
FIN
MDE
NFE
SAS
OTH
V/L rs747738228 0.106 0.001 N 0.202 0.05 0.303781844768 gnomAD-2.1.1 1.21E-05 None None None None N None 0 2.9E-05 None 0 0 None 6.54E-05 None 0 0 0
V/L rs747738228 0.106 0.001 N 0.202 0.05 0.303781844768 gnomAD-4.0.0 1.36874E-06 None None None None N None 0 2.23724E-05 None 0 0 None 0 0 8.99606E-07 0 0

Saturation Mutagenesis

SAV
AlphaMissense (IC)
AlphaMissense Class (IC)
AlphaMissense (N2AB)
AlphaMissense Class (N2AB)
mCSM
mCSM class
PolyPhen-2
PolyPhen-2 Class
Rhapsody
Rhapsody Class
Condel
Condel Score
Site annotation
mCSM PPI
Predicted PPI site
V/A 0.2686 likely_benign 0.2987 benign -0.423 Destabilizing 0.005 N 0.209 neutral N 0.456906655 None None N
V/C 0.6255 likely_pathogenic 0.6218 pathogenic -0.64 Destabilizing 0.628 D 0.348 neutral None None None None N
V/D 0.5286 ambiguous 0.599 pathogenic 0.17 Stabilizing 0.072 N 0.389 neutral None None None None N
V/E 0.4171 ambiguous 0.4526 ambiguous 0.068 Stabilizing 0.055 N 0.371 neutral N 0.456146187 None None N
V/F 0.1424 likely_benign 0.1489 benign -0.631 Destabilizing 0.072 N 0.386 neutral None None None None N
V/G 0.3725 ambiguous 0.4141 ambiguous -0.563 Destabilizing 0.055 N 0.359 neutral N 0.457920613 None None N
V/H 0.4515 ambiguous 0.4757 ambiguous -0.182 Destabilizing 0.864 D 0.329 neutral None None None None N
V/I 0.057 likely_benign 0.0572 benign -0.203 Destabilizing None N 0.148 neutral N 0.370859003 None None N
V/K 0.3362 likely_benign 0.3537 ambiguous -0.18 Destabilizing 0.072 N 0.365 neutral None None None None N
V/L 0.1286 likely_benign 0.1222 benign -0.203 Destabilizing 0.001 N 0.202 neutral N 0.454706964 None None N
V/M 0.1188 likely_benign 0.1152 benign -0.25 Destabilizing 0.214 N 0.365 neutral None None None None N
V/N 0.2482 likely_benign 0.2747 benign 0.043 Stabilizing 0.214 N 0.375 neutral None None None None N
V/P 0.9112 likely_pathogenic 0.9377 pathogenic -0.241 Destabilizing 0.356 N 0.368 neutral None None None None N
V/Q 0.3173 likely_benign 0.3259 benign -0.184 Destabilizing 0.356 N 0.353 neutral None None None None N
V/R 0.2791 likely_benign 0.2955 benign 0.224 Stabilizing 0.214 N 0.367 neutral None None None None N
V/S 0.2409 likely_benign 0.2774 benign -0.413 Destabilizing 0.038 N 0.357 neutral None None None None N
V/T 0.1611 likely_benign 0.1894 benign -0.408 Destabilizing None N 0.133 neutral None None None None N
V/W 0.7433 likely_pathogenic 0.7533 pathogenic -0.692 Destabilizing 0.864 D 0.351 neutral None None None None N
V/Y 0.4287 ambiguous 0.4434 ambiguous -0.358 Destabilizing 0.356 N 0.389 neutral None None None None N

Titin has multiple isoforms, the longest being the theoretical IC (inferred complete) isoform which contains all 363 in-frame titin exons. Here all isoform positions have been mapped onto the IC sequence, with an exception being the C-terminal of the much shorter novex-3 isoform. This contains the out of frame exon 48 which cannot be mapped to the other isoforms.